As for the off-tumor toxicity risks for CARtein constructs targeting SLAMF7 and BCMA, they are expected to be identical to conventional CAR-T therapies using the same humanized scFvs, as the mature CARtein receptor is structurally equivalent except for a 6-amino acid scar. The gene discussed is TNFRSF17; the disease is neoplasm.